EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review

Kübra Kelleci, Adil Allahverdiyev, Melahat Bağirova, Murat Ihlamur, Emrah Ş Abamor

Journal of Vector Borne Diseases · 2023

DOI: 10.4103/0972-9062.361179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Vector Borne Diseases, 2023. Verfasst von Kübra Kelleci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beykoz University, Vocational School, Department of Medical Services and Techniques, Beykoz, Istanbul, Turkey. Hauptthemen laut MEDLINE: Leishmaniasis Vaccines, Leishmaniasis, Visceral, Leishmania, Leishmaniasis, Cutaneous. Die Arbeit wurde bisher 15-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a parasitic disease with different clinical forms caused by protozoan parasites of the genus Leishmania and transmitted by the bite of an infected female sandfly. According to the World Health Organization (WHO), it is the second most common parasitic disease after malaria and it is known that approximately 350 million people are at risk. The disease manifests itself in different clinical forms. In addition to asymptomatic cases, cutaneous leishmaniasis (CL), which creates large lesions on the skin, and visceral leishmaniasis (VL), which causes death if not treated, especially affecting the abdominal organs, are two important clinical forms. When the studies were examined, it was seen that a clinically used vaccine against any form of human leishmaniasis has not been developed yet. In some studies, it was stated that the lack of appropriate adjuvant was responsible for the failure to develop an effective Leishmania vaccine. We can say that strong adjuvants are needed to achieve successful vaccines. In this article, adjuvants and adjuvant candidates used in vaccine studies against leishmaniasis are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis VaccinesLeishmaniasis, VisceralLeishmaniaLeishmaniasis, CutaneousFemaleHumansAdjuvants, Immunologic

Stichwörter der Autor:innen

adjuvantdelivery systemleishmaniasisnanoparticlesvaccination

Substanzen

Leishmaniasis VaccinesAdjuvants, Immunologic

Autor:innen und Institutionen

  • Beykoz University, Vocational School, Department of Medical Services and Techniques, Beykoz, Istanbul, Turkey.
  • V. Akhundov National Scientific Research Medical Prophylactic Institute, Baku, Azerbaijan.
  • Biruni University, Department of Electronics and Automation, Biomedical Device Technologies Program, Istanbul, Turkey.
  • Department of Bioengineering, Yildiz Technical University, Istanbul, Turkey.

Zitieren

APA

Kelleci, K., Allahverdiyev, A., Bağirova, M., Ihlamur, M., & Abamor, E. Ş. (2023). Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review. Journal of Vector Borne Diseases. https://doi.org/10.4103/0972-9062.361179

Vancouver

Kelleci K, Allahverdiyev A, Bağirova M, Ihlamur M, Abamor EŞ. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review. Journal of Vector Borne Diseases. 2023. doi:10.4103/0972-9062.361179

BibTeX
@article{Kelleci2023,
  author = {Kelleci, Kübra and Allahverdiyev, Adil and Bağirova, Melahat and Ihlamur, Murat and Abamor, Emrah Ş},
  title = {Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review},
  journal = {Journal of Vector Borne Diseases},
  year = {2023},
  doi = {10.4103/0972-9062.361179}
}
Kostenlos starten →